AstraZeneca recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer.

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug prices sent shares of pharmaceuticals companies lower across the ...

AstraZeneca has a better P/E ratio of 27.25 than the aggregate P/E ratio of 27.19 of the Pharmaceuticals industry. Ideally, one might believe that AstraZeneca Inc. might perform better in the ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

On Thursday, May 8, 2025, a three-judge panel of the Third Circuit affirmed the district court’s rejection of AstraZeneca’s constitutional and regulatory challenge to the Negotiation Program.

So on that alone, maybe yes. But what might this new US move mean for the industry overall, and for AstraZeneca shares specifically? Analyst Stefan Schneider at Bank Vontobel said it “has the ...

The AstraZeneca share price has pulled back in recent months. Dr James Fox explores how the stock compares with pharma peer GSK. When investing, your capital is at risk. The value of your ...

The AstraZeneca (LSE: AZN) share price slumped 5% when the market opened on Monday (12 May). Fellow UK pharma giant GSK dipped too, losing 3.5% in early trading. Both regained a bit, with AstraZeneca ...